FUM vs. SCLP, FARN, 4BB, AVCT, POLB, ETX, TRX, AREC, REDX, and HVO
Should you be buying Futura Medical stock or one of its competitors? The main competitors of Futura Medical include Scancell (SCLP), Faron Pharmaceuticals Oy (FARN), 4basebio (4BB), Avacta Group (AVCT), Poolbeg Pharma (POLB), e-therapeutics (ETX), Tissue Regenix Group (TRX), Arecor Therapeutics (AREC), Redx Pharma (REDX), and hVIVO (HVO). These companies are all part of the "biotechnology" industry.
Scancell (LON:SCLP) and Futura Medical (LON:FUM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings, valuation and community ranking.
In the previous week, Scancell had 1 more articles in the media than Futura Medical. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Futura Medical. Futura Medical's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.
Scancell received 1 more outperform votes than Futura Medical when rated by MarketBeat users. Likewise, 74.50% of users gave Scancell an outperform vote while only 64.36% of users gave Futura Medical an outperform vote.
Futura Medical has lower revenue, but higher earnings than Scancell. Futura Medical is trading at a lower price-to-earnings ratio than Scancell, indicating that it is currently the more affordable of the two stocks.
Scancell has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, Futura Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
45.7% of Scancell shares are owned by institutional investors. Comparatively, 36.0% of Futura Medical shares are owned by institutional investors. 5.7% of Scancell shares are owned by company insiders. Comparatively, 32.9% of Futura Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Scancell has a net margin of 0.00% compared to Scancell's net margin of -299.73%. Scancell's return on equity of -66.35% beat Futura Medical's return on equity.
Summary
Scancell beats Futura Medical on 9 of the 14 factors compared between the two stocks.
Get Futura Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for FUM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FUM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Futura Medical Competitors List
Related Companies and Tools
